Latest News Archive

Please select Category, Year, and then Month to display items
Categories
UFS News Media Release Research
Years
2017 2018 2019 2020 2021 2022 2023 2024
Months
January February March April May June July August September October November December
Previous Archive
14 August 2020 | Story Amanda Tongha | Photo NSFAS
Applications for the National Student Financial Aid Scheme (NSFAS) 2021 are now open.  

The NSFAS application cycle will run for a period of four months starting from 3 August to 30 November 2020. 

NSFAS applications are open to students from poor and working-class backgrounds who wish to further their studies at any public Technical and Vocational Education and Training (TVET) college or university. To qualify for NSFAS funding, the applicant must be a South African citizen; come from a family with a combined annual household income of not more than R350 000; for students with a disability, a combined annual household income of not more than R600 000. 

Applications for 2021 funding will be completed online via the myNSFAS portal as per previous years. 

New applicants need a copy of their ID or birth certificate to register and create a myNSFAS account or profile on the myNSFAS portal. Applicants with existing accounts must log on to their accounts to complete an application. Applicants are not allowed to create more than one profile on the portal. The applicant will be required to give consent to NSFAS to verify their personal information with third parties and will not be able to create a profile without giving this consent. This feature allows NSFAS to conduct a three-step verification process with the Department of Home Affairs (DHA), where an ID number will be linked to the name and surname of the applicant and the parents' details. 

In response to the status quo due to the COVID-19 pandemic, applicants will not be required to submit or upload the consent form; however, they will have to grant consent electronically during the application process, along with accepting the terms and conditions for funding. 

Applicants will, however, still be required to submit their supporting documents, comprising a copy of own ID; parents’/guardian's proof of income; copies of parents’/guardian's ID; and/or Annexure A for applicants with disabilities. 

Qualifying students are urged to make use of this opportunity and apply for funding in time. 

 
 

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept